Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 129-135

  Mohammed, Eman E A ^a   Snella, Elizabeth M ^a   Rutz Mendicino, Michelle M ^a   Echevarria, Franklin D ^a   Awedikian, Rafi ^a   Whitley, Elizabeth M ^a   Ellinwood, N Matthew ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Double knockout model; GalNAc transferase; Mucopolysaccharidosis type IIIB

Indexed keywords

BETA 1,4 N ACETYLGALACTOSAMINYLTRANSFERASE; GANGLIOSIDE; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CONTROLLED STUDY; CORPUS CALLOSUM; FEMALE; HISTOPATHOLOGY; LIFESPAN; MOTOR PERFORMANCE; MOUSE; MUCOPOLYSACCHARIDOSIS; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SANFILIPPO SYNDROME TYPE B; SURVIVAL;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GLYCOSPHINGOLIPIDS; MALE; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS III; N-ACETYLGALACTOSAMINYLTRANSFERASES; ROTAROD PERFORMANCE TEST;

MUS;

EID: 84866150028     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.07.017     Document Type: Article

References (40)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, Health Professions Division, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Platt F.M., Jeyakumar M. Substrate reduction therapy. Acta Paediatr. Suppl. 2008, 97:88-93.
3. Li H.H., Yu W.H., Rozengurt N., Zhao H.Z., Lyons K.M., Anagnostaras S., Fanselow M.S., Suzuki K., Vanier M.T., Neufeld E.F. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14505-14510.
4. Fischer A., Carmichael K.P., Munnell J.F., Jhabvala P., Thompson J.N., Matalon R., Jezyk P.F., Wang P., Giger U. Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA. Pediatr. Res. 1998, 44:74-82.
5. Constantopoulos G., Shull R.M., Hastings N., Neufeld E.F. Neurochemical characterization of canine alpha-L-iduronidase deficiency disease. J. Neurochem. 1985, 45:1213-1217.
6. Constantopoulos G., Iqbal K., Dekaban A.S. Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J. Neurochem. 1980, 34:1399-1411.
7. Jones M.Z., Alroy J., Rutledge J.C., Taylor J.W., Alvord E.C., Toone J., Applegarth D., Hopwood J.J., Skutelsky E., Ianelli C., Thorley-Lawson D., Mitchell-Herpolsheimer C., Arias A., Sharp P., Evans W., Sillence D., Cavanagh K.T. Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics. J. Neuropathol. Exp. Neurol. 1997, 56:1158-1167.
8. Jones M.Z., Alroy J., Boyer P.J., Cavanagh K.T., Johnson K., Gage D., Vorro J., Render J.A., Common R.S., Leedle R.A., Lowrie C., Sharp P., Liour S.S., Levene B., Hoard H., Lucas R., Hopwood J.J. Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics. J. Neuropathol. Exp. Neurol. 1998, 57:148-157.
9. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., Stanley P. A mouse model for mucopolysaccharidosis type III A. Glycobiology 1999, 9:1389-1396.
10. Dekaban A.S., Patton V.M. Hurler's and Sanfilippo's variants of mucopolysaccharidosis. Cerebral pathology and lipid chemistry. Arch. Pathol. 1971, 91:434-443.
11. Ellinwood N.M., Verot L., Colle M.-A., Giger U., Vanier M.T., Haskins M.E. Canine mucopolysaccharidosis IIIB: aspects of visceral and brain pathology. American Society of Human Genetics 54th Annual Meeting, Toronto, Ontario, Canada 2004, 317.
12. Walkley S.U., Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta 2004, 1685:48-62.
13. Takamiya K., Yamamoto A., Furukawa K., Zhao J., Fukumoto S., Yamashiro S., Okada M., Haraguchi M., Shin M., Kishikawa M., Shiku H., Aizawa S., Furukawa K. Complex gangliosides are essential in spermatogenesis of mice: possible roles in the transport of testosterone. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12147-12152.
14. Zhao J., Furukawa K., Fukumoto S., Okada M., Furugen R., Miyazaki H., Takamiya K., Aizawa S., Shiku H., Matsuyama T., Furukawa K. Attenuation of interleukin 2 signal in the spleen cells of complex ganglioside-lacking mice. J. Biol. Chem. 1999, 274:13744-13747.
15. Takamiya K., Yamamoto A., Furukawa K., Yamashiro S., Shin M., Okada M., Fukumoto S., Haraguchi M., Takeda N., Fujimura K., Sakae M., Kishikawa M., Shiku H., Aizawa S. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10662-10667.
16. Sheikh K.A., Sun J., Liu Y., Kawai H., Crawford T.O., Proia R.L., Griffin J.W., Schnaar R.L. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7532-7537.
17. Furukawa K., Takamiya K. Beta1,4-N-acetylgalactosaminyltransferase-GM2/GD2 synthase: a key enzyme to control the synthesis of brain-enriched complex gangliosides. Biochim. Biophys. Acta 2002, 1573:356-362.
18. Chiavegatto S., Sun J., Nelson R.J., Schnaar R.L. A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. Exp. Neurol. 2000, 166:227-234.
19. Yamashita T., Wu Y.P., Sandhoff R., Werth N., Mizukami H., Ellis J.M., Dupree J.L., Geyer R., Sandhoff K., Proia R.L. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2725-2730.
20. Pan B., Fromholt S.E., Hess E.J., Crawford T.O., Griffin J.W., Sheikh K.A., Schnaar R.L. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp. Neurol. 2005, 195:208-217.
21. Ohmi Y., Tajima O., Ohkawa Y., Mori A., Sugiura Y., Furukawa K., Furukawa K. Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:22405-22410.
22. Walkley S.U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 2004, 15:433-444.
23. Walkley S.U., Zervas M., Wiseman S. Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. Cereb. Cortex 2000, 10:1028-1037.
24. Walkley S.U. Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivity. Neuroscience 1995, 68:1027-1035.
25. Walkley S.U. Neurobiology and cellular pathogenesis of glycolipid storage diseases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:893-904.
26. Sango K., Johnson O.N., Kozak C.A., Proia R.L. beta-1,4-N-Acetylgalactosaminyltransferase involved in ganglioside synthesis: cDNA sequence, expression, and chromosome mapping of the mouse gene. Genomics 1995, 27:362-365.
27. Liu Y., Wada R., Kawai H., Sango K., Deng C., Tai T., McDonald M.P., Araujo K., Crawley J.N., Bierfreund U., Sandhoff K., Suzuki K., Proia R.L. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest. 1999, 103:497-505.
28. Liu Y., Wu Y.P., Wada R., Neufeld E.B., Mullin K.A., Howard A.C., Pentchev P.G., Vanier M.T., Suzuki K., Proia R.L. Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse. Hum. Mol. Genet. 2000, 9:1087-1092.
29. Gondre-Lewis M.C., McGlynn R., Walkley S.U. Cholesterol accumulation in NPC1-deficient neurons is ganglioside dependent. Curr. Biol. 2003, 13:1324-1329.
30. AVMA Report of the AVMA Panel on Euthanasia, JAVMA 2001, 669-696.
31. Truett G.E., Heeger P., Mynatt R.L., Truett A.A., Walker J.A., Warman M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 2000, 29:52-54.
32. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53:457-481.
33. Heldermon C.D., Hennig A.K., Ohlemiller K.K., Ogilvie J.M., Herzog E.D., Breidenbach A., Vogler C., Wozniak D.F., Sands M.S. Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2007, 2:e772.
34. Fujita N., Suzuki K., Vanier M.T., Popko B., Maeda N., Klein A., Henseler M., Sandhoff K., Nakayasu H., Suzuki K. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 1996, 5:711-725.
35. Kyrklund T. Two procedures to remove polar contaminants from a crude brain lipid extract by using prepacked reversed-phase columns. Lipids 1987, 22:274-277.
36. Guffon N., Bin-Dorel S., Decullier E., Paillet C., Guitton J., Fouilhoux A. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J. Pediatr. 2011.
37. Gografe S.I., Sanberg P.R., Chamizo W., Monforte H., Garbuzova-Davis S. Novel pathologic findings associated with urinary retention in a mouse model of mucopolysaccharidosis type IIIB. Comp. Med. 2009, 59:139-146.
38. McGlynn R., Dobrenis K., Walkley S.U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J. Comp. Neurol. 2004, 480:415-426.
39. Morales A., Colell A., Mari M., Garcia-Ruiz C., Fernandez-Checa J.C. Glycosphingolipids and mitochondria: role in apoptosis and disease. Glycoconj. J. 2004, 20:579-588.
40. Schnaar R.L. Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Lett. 2010, 584:1741-1747.